Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity

Mustafa Taleb Ardah, Katerina E. Paleologou, Guohua Lv, Salema Begum Abul Khair, Abdullah KazimAl Kendi, Saeed Tarek Minhas, Taleb H. Al-Tel, Abdulmonem A. Al-Hayani, Mohammed Emdadul Haque, David Eliezer, Omar Ali El-Agnaf

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The aggregation of α-synuclein (α-syn) is considered the key pathogenic event in many neurological disorders such as Parkinson's disease (PD), dementia with Lewy bodies and multiple system atrophy, giving rise to a whole category of neurodegenerative diseases known as synucleinopathies. Although the molecular basis of α-syn toxicity has not been precisely elucidated, a great deal of effort has been put into identifying compounds that could inhibit or even reverse the aggregation process. Previous reports indicated that many phenolic compounds are potent inhibitors of α-syn aggregation. The aim of the present study was to assess the anti-aggregating effect of gallic acid (GA) (3,4,5-trihydroxybenzoic acid), a benzoic acid derivative that belongs to a group of phenolic compounds known as phenolic acids. By employing an array of biophysical and biochemical techniques and a cell-viability assay, GA was shown not only to inhibit α-syn fibrillation and toxicity but also to disaggregate preformed α-syn amyloid fibrils. Interestingly, GA was found to bind to soluble, non33 toxic oligomers with no β-sheet content, and to stabilize their structure. The binding of GA to the oligomers may represent a potential mechanism of action. Additionally, by using structure activity relationship data obtained from fourteen structurally similar benzoic acid derivatives, it was determined that the inhibition of α-syn fibrillation by GA is related to the number of hydroxyl moieties and their position on the phenyl ring. GA may represent the starting point for designing new molecules that could be used for the treatment of PD and related disorders.

Original languageEnglish
Article number197
JournalFrontiers in Aging Neuroscience
Volume6
Issue numberJUL
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Synucleins
Gallic Acid
Structure-Activity Relationship
Benzoic Acid
Parkinson Disease
Multiple System Atrophy
Lewy Body Disease
Poisons
phenolic acid
Nervous System Diseases
Amyloid
Neurodegenerative Diseases
Hydroxyl Radical
Action Potentials
Cell Survival

Keywords

  • Aggregation
  • Amyloid fibrils
  • Drug discovery
  • Gallic acid
  • Parkinson's disease
  • α-Synuclein

ASJC Scopus subject areas

  • Ageing
  • Cognitive Neuroscience

Cite this

Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity. / Ardah, Mustafa Taleb; Paleologou, Katerina E.; Lv, Guohua; Khair, Salema Begum Abul; Kendi, Abdullah KazimAl; Minhas, Saeed Tarek; Al-Tel, Taleb H.; Al-Hayani, Abdulmonem A.; Haque, Mohammed Emdadul; Eliezer, David; Ali El-Agnaf, Omar.

In: Frontiers in Aging Neuroscience, Vol. 6, No. JUL, 197, 2014.

Research output: Contribution to journalArticle

Ardah, MT, Paleologou, KE, Lv, G, Khair, SBA, Kendi, AK, Minhas, ST, Al-Tel, TH, Al-Hayani, AA, Haque, ME, Eliezer, D & Ali El-Agnaf, O 2014, 'Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity', Frontiers in Aging Neuroscience, vol. 6, no. JUL, 197. https://doi.org/10.3389/fnagi.2014.00197
Ardah, Mustafa Taleb ; Paleologou, Katerina E. ; Lv, Guohua ; Khair, Salema Begum Abul ; Kendi, Abdullah KazimAl ; Minhas, Saeed Tarek ; Al-Tel, Taleb H. ; Al-Hayani, Abdulmonem A. ; Haque, Mohammed Emdadul ; Eliezer, David ; Ali El-Agnaf, Omar. / Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity. In: Frontiers in Aging Neuroscience. 2014 ; Vol. 6, No. JUL.
@article{5168532c92674b48ab95abf82c280235,
title = "Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity",
abstract = "The aggregation of α-synuclein (α-syn) is considered the key pathogenic event in many neurological disorders such as Parkinson's disease (PD), dementia with Lewy bodies and multiple system atrophy, giving rise to a whole category of neurodegenerative diseases known as synucleinopathies. Although the molecular basis of α-syn toxicity has not been precisely elucidated, a great deal of effort has been put into identifying compounds that could inhibit or even reverse the aggregation process. Previous reports indicated that many phenolic compounds are potent inhibitors of α-syn aggregation. The aim of the present study was to assess the anti-aggregating effect of gallic acid (GA) (3,4,5-trihydroxybenzoic acid), a benzoic acid derivative that belongs to a group of phenolic compounds known as phenolic acids. By employing an array of biophysical and biochemical techniques and a cell-viability assay, GA was shown not only to inhibit α-syn fibrillation and toxicity but also to disaggregate preformed α-syn amyloid fibrils. Interestingly, GA was found to bind to soluble, non33 toxic oligomers with no β-sheet content, and to stabilize their structure. The binding of GA to the oligomers may represent a potential mechanism of action. Additionally, by using structure activity relationship data obtained from fourteen structurally similar benzoic acid derivatives, it was determined that the inhibition of α-syn fibrillation by GA is related to the number of hydroxyl moieties and their position on the phenyl ring. GA may represent the starting point for designing new molecules that could be used for the treatment of PD and related disorders.",
keywords = "Aggregation, Amyloid fibrils, Drug discovery, Gallic acid, Parkinson's disease, α-Synuclein",
author = "Ardah, {Mustafa Taleb} and Paleologou, {Katerina E.} and Guohua Lv and Khair, {Salema Begum Abul} and Kendi, {Abdullah KazimAl} and Minhas, {Saeed Tarek} and Al-Tel, {Taleb H.} and Al-Hayani, {Abdulmonem A.} and Haque, {Mohammed Emdadul} and David Eliezer and {Ali El-Agnaf}, Omar",
year = "2014",
doi = "10.3389/fnagi.2014.00197",
language = "English",
volume = "6",
journal = "Frontiers in Aging Neuroscience",
issn = "1663-4365",
publisher = "Frontiers Research Foundation",
number = "JUL",

}

TY - JOUR

T1 - Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity

AU - Ardah, Mustafa Taleb

AU - Paleologou, Katerina E.

AU - Lv, Guohua

AU - Khair, Salema Begum Abul

AU - Kendi, Abdullah KazimAl

AU - Minhas, Saeed Tarek

AU - Al-Tel, Taleb H.

AU - Al-Hayani, Abdulmonem A.

AU - Haque, Mohammed Emdadul

AU - Eliezer, David

AU - Ali El-Agnaf, Omar

PY - 2014

Y1 - 2014

N2 - The aggregation of α-synuclein (α-syn) is considered the key pathogenic event in many neurological disorders such as Parkinson's disease (PD), dementia with Lewy bodies and multiple system atrophy, giving rise to a whole category of neurodegenerative diseases known as synucleinopathies. Although the molecular basis of α-syn toxicity has not been precisely elucidated, a great deal of effort has been put into identifying compounds that could inhibit or even reverse the aggregation process. Previous reports indicated that many phenolic compounds are potent inhibitors of α-syn aggregation. The aim of the present study was to assess the anti-aggregating effect of gallic acid (GA) (3,4,5-trihydroxybenzoic acid), a benzoic acid derivative that belongs to a group of phenolic compounds known as phenolic acids. By employing an array of biophysical and biochemical techniques and a cell-viability assay, GA was shown not only to inhibit α-syn fibrillation and toxicity but also to disaggregate preformed α-syn amyloid fibrils. Interestingly, GA was found to bind to soluble, non33 toxic oligomers with no β-sheet content, and to stabilize their structure. The binding of GA to the oligomers may represent a potential mechanism of action. Additionally, by using structure activity relationship data obtained from fourteen structurally similar benzoic acid derivatives, it was determined that the inhibition of α-syn fibrillation by GA is related to the number of hydroxyl moieties and their position on the phenyl ring. GA may represent the starting point for designing new molecules that could be used for the treatment of PD and related disorders.

AB - The aggregation of α-synuclein (α-syn) is considered the key pathogenic event in many neurological disorders such as Parkinson's disease (PD), dementia with Lewy bodies and multiple system atrophy, giving rise to a whole category of neurodegenerative diseases known as synucleinopathies. Although the molecular basis of α-syn toxicity has not been precisely elucidated, a great deal of effort has been put into identifying compounds that could inhibit or even reverse the aggregation process. Previous reports indicated that many phenolic compounds are potent inhibitors of α-syn aggregation. The aim of the present study was to assess the anti-aggregating effect of gallic acid (GA) (3,4,5-trihydroxybenzoic acid), a benzoic acid derivative that belongs to a group of phenolic compounds known as phenolic acids. By employing an array of biophysical and biochemical techniques and a cell-viability assay, GA was shown not only to inhibit α-syn fibrillation and toxicity but also to disaggregate preformed α-syn amyloid fibrils. Interestingly, GA was found to bind to soluble, non33 toxic oligomers with no β-sheet content, and to stabilize their structure. The binding of GA to the oligomers may represent a potential mechanism of action. Additionally, by using structure activity relationship data obtained from fourteen structurally similar benzoic acid derivatives, it was determined that the inhibition of α-syn fibrillation by GA is related to the number of hydroxyl moieties and their position on the phenyl ring. GA may represent the starting point for designing new molecules that could be used for the treatment of PD and related disorders.

KW - Aggregation

KW - Amyloid fibrils

KW - Drug discovery

KW - Gallic acid

KW - Parkinson's disease

KW - α-Synuclein

UR - http://www.scopus.com/inward/record.url?scp=84904637112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904637112&partnerID=8YFLogxK

U2 - 10.3389/fnagi.2014.00197

DO - 10.3389/fnagi.2014.00197

M3 - Article

VL - 6

JO - Frontiers in Aging Neuroscience

JF - Frontiers in Aging Neuroscience

SN - 1663-4365

IS - JUL

M1 - 197

ER -